Sumitomo Chemicals gains from new products, parent-led capex and monsoon recovery
Sumitomo Chemical India Ltd.
BUY
₹525
₹515.95
₹625
19.05%
Investment View and Key Thesis
In its August 10, 2026 report, ICICI Direct Research described Sumitomo Chemicals’ Q1FY27 performance as resilient despite weather-related headwinds and retained its positive outlook. The brokerage maintained its BUY recommendation with a target price of Rs 625, compared with a CMP of Rs 525.
Sumitomo Chemicals is an Indian subsidiary of Sumitomo Chemical Company, Japan, providing insecticides, herbicides, metal phosphates, fungicides and related solutions. ICICI Direct’s thesis is supported by new-product momentum, closer engagement with the Japanese parent and a potential recovery in monsoon-led agricultural demand.
Business Mix and Q1FY27 Performance
In Q1FY27, insecticides represented about 35 per cent of the product mix, herbicides about 31 per cent, plant growth regulators about 6 per cent and fungicides about 5 per cent. The reported geographic mix was India at about 87 per cent and exports at about 13 per cent.
| Metric | Q1FY27 performance |
|---|---|
| Revenue | Rs 1,063 crore; flat year on year |
| Insecticide revenue | 35 per cent of sales; flat year on year |
| Herbicide revenue | 31 per cent of sales; declined 8 per cent year on year |
| Metal phosphates | 10 per cent of revenue; grew 26 per cent year on year |
| Animal Nutrition and Environmental Health divisions | 13 per cent of revenue; grew 19 per cent year on year |
| Domestic revenue | Declined about 3 per cent to Rs 893 crore, or 84 per cent of reported revenue |
| Export revenue | Rose about 26 per cent to Rs 170 crore, or 16 per cent of reported revenue |
| Gross margin | 39.2 per cent, up about 110 basis points year on year |
| EBITDA | Rs 233 crore, up 6 per cent year on year |
| EBITDA margin | 21.9 per cent, up about 120 basis points year on year |
| PAT | Rs 214 crore, up about 20 per cent year on year |
Gross margin expansion was supported by price increases, while EBITDA and PAT growth outpaced revenue growth during the quarter.
Monsoon and Agricultural Demand Outlook
The June quarter was affected by a delayed South-West monsoon, including a 40 per cent rainfall deficit until June-end, lower reservoir levels and an approximately 20 per cent decline in kharif sowing during the early season. The comparison was also demanding because Q1FY26 benefited from an early monsoon onset in May 2025 and associated inventory filling.
ICICI Direct expects sowing activity to recover because the South-West monsoon had covered almost all of India and the cumulative rainfall deficit had narrowed to 11 per cent in August.
New-Product Momentum
New-product momentum is a central driver of ICICI Direct’s thesis. Sumitomo Chemicals launched seven large products in FY26, including Lentigo, Excalia Max, Powerpull, Advika, Envoy and Oslava. Lentigo and Excalia Max received a favourable market response and exceeded the company’s internal targets, while the broader launch set is expected to gain meaningful traction.
Topgrain and Helibax, a Pyridalyl plus Emamectin product, remained on track for launch in Q2FY27. The company also had three to four Sumitomo Chemical Company parent products in the launch pipeline.
Parent Engagement and Capacity Expansion
ICICI Direct sees closer parent engagement as a differentiating factor for Sumitomo Chemicals compared with other multinational agrochemical players and believes it supports a premium valuation. Sumitomo Chemicals has been elevated to the same tier as Japan, the US, Brazil and Europe for early-stage new-molecule trials.
Sumitomo Chemical Company is also evaluating a potential foray into semiconductor chemicals through Sumitomo Chemicals in India. A Rs 150 crore Dahej capex project to manufacture high-value patented molecules for the parent remains on track, with commercialisation expected from Q2FY29. Bhavnagar and Tarapur projects serving parent requirements are targeted for commissioning by Q4FY27. Announcements in May 2025 and January 2026 together represented approximately Rs 225 crore of capex.
Earnings Estimates and Valuation
ICICI Direct maintained its BUY recommendation and Rs 625 target price, based on 45 times FY28E EPS of Rs 13.9.
| Financial estimate | FY27E | FY28E |
|---|---|---|
| Revenue | Rs 3,557 crore | Rs 4,007 crore |
| EBITDA | Rs 800 crore | Rs 922 crore |
| EBITDA margin | 22.5 per cent | 23.0 per cent |
Key Risks
- Lower-than-expected offtake of new products.
- Adverse weather conditions in domestic and export markets.
Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.
